NDAORALTABLET
Approved
Mar 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
DIOVAN HCT (valsartan and hydrochlorothiazide) by Novartis is angiotensin 2 receptor antagonists [moa]. Approved for angiotensin 2 receptor blocker [epc]. First approved in 1998.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIOVAN HCT is a fixed-dose combination oral tablet containing valsartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) approved in 1998. It is indicated for hypertension management, combining two complementary mechanisms to reduce blood pressure. The drug works by blocking angiotensin II receptors and promoting sodium and water excretion, making it effective for patients requiring dual antihypertensive therapy.
$8MPart D
LOE ApproachingDeclining
Spending and claims remain modest at $8M and 8,763 claims in 2023, indicating a mature product with limited team expansion opportunities and focus on margin protection rather than growth initiatives.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Started Oct 2006
601 enrolled
Hypertension
Career Relevance
DIOVAN HCT currently has zero linked job openings, reflecting its mature, declining commercial status approaching LOE. Career opportunities on this product are limited to defensive commercial roles such as generic competition management, pricing/reimbursement, and operational efficiency—not growth initiatives.
Brand Manager
Worked on DIOVAN HCT at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.